AMENDMENTS TO THE CLAIMS PURSUANT TO 37 CFR § 1.21

1. (Presently Amended) A method, comprising:

   a) providing;

      i) a human presenting symptoms of sepsis, and

      ii) a therapeutic composition comprising ~~an antibody, wherein said~~ antibody ~~consists of an antibody~~ specific for SEQ ID NO:5, wherein said composition is not reactive with the C-terminal region of C5a peptide; and

   b) administering said therapeutic composition to said human under conditions such that at least one ~~of said~~ symptoms is reduced.

2. (Canceled)

3. (Original) The method of Claim 1, wherein said human presents the symptoms of sepsis for a period in the range of approximately six to twelve hours prior to the administration of said therapeutic composition.

4. (Canceled)

5. (Original) The method of Claim 1, wherein said antibody is polyclonal.

6. (Original) The method of Claim 1, wherein said antibody is monoclonal.

7. (Original) The method of Claim 1, wherein said antibody is not reactive with complement component C5.